{"id":"NCT00310804","sponsor":"Novartis Vaccines","briefTitle":"Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to <=60)","officialTitle":"A Phase III, Randomized, Controlled, Observer-Blind, Multi-Center Study to Evaluate Safety, Tolerability and Immunogenicity of a Single Intramuscular Dose of Three Lots of a Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture Or of a Trivalent Subunit Influenza Vaccine Produced in Embryonated Hen Eggs, in Healthy Adult Subjects Aged >=18 to <=60","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-09","primaryCompletion":"2005-10","completion":"2006-04","firstPosted":"2006-04-05","resultsPosted":"2013-01-18","lastUpdate":"2019-08-15"},"enrollment":1200,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"Cell-Derived Trivalent Subunit Influenza Vaccine Lot 1 (cTIV)","otherNames":[]},{"type":"BIOLOGICAL","name":"Cell-Derived Trivalent Subunit Influenza Vaccine Lot 2 (cTIV)","otherNames":[]},{"type":"BIOLOGICAL","name":"Cell-Derived Trivalent Subunit Influenza Vaccine Lot 3 (cTIV)","otherNames":[]},{"type":"BIOLOGICAL","name":"Egg-Derived Trivalent Subunit Influenza Vaccine (TIV)","otherNames":[]}],"arms":[{"label":"cTIV_lot 1","type":"EXPERIMENTAL"},{"label":"cTIV_lot 2","type":"EXPERIMENTAL"},{"label":"cTIV_lot 3","type":"EXPERIMENTAL"},{"label":"TIV group","type":"ACTIVE_COMPARATOR"}],"summary":"The present study aims to evaluate safety, tolerability and immunogenicity of three lots of Chiron's cell-derived subunit influenza vaccine in healthy adult subjects as compared to a conventional egg-derived control vaccine licensed in Europe.","primaryOutcome":{"measure":"Geometric Mean Titers After One Dose of Cell Culture-derived or the Egg-derived Influenza Vaccine in Adult Subjects","timeFrame":"Day 22 postvaccination","effectByArm":[{"arm":"cTIV_lot1","deltaMin":12,"sd":null},{"arm":"cTIV_lot 2","deltaMin":15,"sd":null},{"arm":"cTIV_lot3","deltaMin":16,"sd":null},{"arm":"cTIV (Combined)","deltaMin":14,"sd":null},{"arm":"TIV Group","deltaMin":15,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":2,"countries":["Lithuania"]},"refs":{"pmids":["19666152"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":599},"commonTop":["Fatigue","Headache","Malaise","Injection Site Pain","Injection Site Erythema"]}}